Structure-Guided Design of an Anti-dengue Antibody Directed to a Non-immunodominant Epitope

Dengue is the most common vector-borne viral disease, causing nearly 400 million infections yearly. Currently there are no approved therapies. Antibody epitopes that elicit weak humoral responses may not be accessible by conventional B cell panning methods. To demonstrate an alternative strategy to generating a therapeutic antibody, we employed a non-immunodominant, but functionally relevant, epitope in domain III of the E protein, and engineered by structure-guided methods an antibody directed to it. The resulting antibody, Ab513, exhibits high-affinity binding to, and broadly neutralizes, multiple genotypes within all four serotypes. To assess therapeutic relevance of Ab513, activity against important human clinical features of dengue was investigated. Ab513 mitigates thrombocytopenia in a humanized mouse model, resolves vascular leakage, reduces viremia to nearly undetectable levels, and protects mice in a maternal transfer model of lethal antibody-mediated enhancement. The results demonstrate that Ab513 may reduce the public health burden from dengue.

[1]  Kenneth G. C. Smith,et al.  The Structural Basis for Serotype-Specific Neutralization of Dengue Virus by a Human Antibody , 2012, Science Translational Medicine.

[2]  C. Huang,et al.  Recombinant Dengue Type 2 Viruses with Altered E Protein Domain III Epitopes Are Efficiently Neutralized by Human Immune Sera , 2012, Journal of Virology.

[3]  Michael S. Seaman,et al.  Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117 , 2015, Nature.

[4]  Cameron P Simmons,et al.  A new class of highly potent, broadly neutralizing antibodies isolated from viremic patients infected with dengue virus , 2014, Nature Immunology.

[5]  Saravudh Suvannadabba,et al.  Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial , 2012, The Lancet.

[6]  Qing Zhu,et al.  Rapid development of broadly influenza neutralizing antibodies through redundant mutations , 2014, Nature.

[7]  Richard J Kuhn,et al.  Binding of a neutralizing antibody to dengue virus alters the arrangement of surface glycoproteins , 2008, Nature Structural &Molecular Biology.

[8]  B. Yan,et al.  First Experimental In Vivo Model of Enhanced Dengue Disease Severity through Maternally Acquired Heterotypic Dengue Antibodies , 2014, PLoS pathogens.

[9]  P. Pitisuttithum,et al.  Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial , 2014, The Lancet.

[10]  M. Diamond,et al.  Identification of human neutralizing antibodies that bind to complex epitopes on dengue virions , 2012, Proceedings of the National Academy of Sciences.

[11]  C. G. Wu,et al.  Hepatitis C virus epitope-specific neutralizing antibodies in Igs prepared from human plasma , 2007, Proceedings of the National Academy of Sciences.

[12]  Prida Malasit,et al.  Cross-Reacting Antibodies Enhance Dengue Virus Infection in Humans , 2010, Science.

[13]  H. Wolfson,et al.  Shape complementarity at protein–protein interfaces , 1994, Biopolymers.

[14]  Soila Sukupolvi-Petty,et al.  Functional Analysis of Antibodies against Dengue Virus Type 4 Reveals Strain-Dependent Epitope Exposure That Impacts Neutralization and Protection , 2013, Journal of Virology.

[15]  Luke N Robinson,et al.  Redesign of a cross-reactive antibody to dengue virus with broad-spectrum activity and increased in vivo potency , 2013, Proceedings of the National Academy of Sciences.

[16]  M. Nussenzweig,et al.  Polyreactive antibodies in adaptive immune responses to viruses , 2011, Cellular and Molecular Life Sciences.

[17]  M. Nussenzweig,et al.  Predominant Autoantibody Production by Early Human B Cell Precursors , 2003, Science.

[18]  A. Lesk,et al.  Conformations of immunoglobulin hypervariable regions , 1989, Nature.

[19]  Cameron P Simmons,et al.  The human immune response to Dengue virus is dominated by highly cross-reactive antibodies endowed with neutralizing and enhancing activity. , 2010, Cell host & microbe.

[20]  Soila Sukupolvi-Petty,et al.  Genotype-Specific Neutralization and Protection by Antibodies against Dengue Virus Type 3 , 2010, Journal of Virology.

[21]  Randy J. Read,et al.  Overview of the CCP4 suite and current developments , 2011, Acta crystallographica. Section D, Biological crystallography.

[22]  Subhash G. Vasudevan,et al.  Ligation of Fc gamma receptor IIB inhibits antibody-dependent enhancement of dengue virus infection , 2011, Proceedings of the National Academy of Sciences.

[23]  E. Harris,et al.  Antibodies targeting dengue virus envelope domain III are not required for serotype-specific protection or prevention of enhancement in vivo. , 2012, Virology.

[24]  E. Harris,et al.  Analysis of Cross-Reactive Antibodies Recognizing the Fusion Loop of Envelope Protein and Correlation with Neutralizing Antibody Titers in Nicaraguan Dengue Cases , 2013, PLoS neglected tropical diseases.

[25]  M. Accavitti-Loper,et al.  Dengue virus neutralization by human immune sera: role of envelope protein domain III-reactive antibody. , 2009, Virology.

[26]  J. Farrar,et al.  Therapeutics for Dengue: Recommendations for Design and Conduct of Early-Phase Clinical Trials , 2012, PLoS neglected tropical diseases.

[27]  A. Nisalak,et al.  Dengue plaque reduction neutralization test (PRNT) in primary and secondary dengue virus infections: How alterations in assay conditions impact performance. , 2009, The American journal of tropical medicine and hygiene.

[28]  C. Thompson,et al.  Interference of immune globulin with measles and rubella immunization. , 1993, European journal of pediatrics.

[29]  Soila Sukupolvi-Petty,et al.  The Potent and Broadly Neutralizing Human Dengue Virus-Specific Monoclonal Antibody 1C19 Reveals a Unique Cross-Reactive Epitope on the bc Loop of Domain II of the Envelope Protein , 2013, mBio.

[30]  Jianzhu Chen,et al.  Inhibition of Megakaryocyte Development in the Bone Marrow Underlies Dengue Virus-Induced Thrombocytopenia in Humanized Mice , 2013, Journal of Virology.

[31]  G. Chang,et al.  Antibodies to Envelope Glycoprotein of Dengue Virus during the Natural Course of Infection Are Predominantly Cross-Reactive and Recognize Epitopes Containing Highly Conserved Residues at the Fusion Loop of Domain II , 2008, Journal of Virology.

[32]  M. K. Gentry,et al.  Dengue virus-specific and flavivirus group determinants identified with monoclonal antibodies by indirect immunofluorescence. , 1982, The American journal of tropical medicine and hygiene.

[33]  P. Evans,et al.  Scaling and assessment of data quality. , 2006, Acta crystallographica. Section D, Biological crystallography.

[34]  D. Cummings,et al.  Variation in dengue virus plaque reduction neutralization testing: systematic review and pooled analysis , 2012, BMC Infectious Diseases.

[35]  G. Carrasquilla,et al.  Efficacy of a tetravalent dengue vaccine in children in Latin America. , 2015, The New England journal of medicine.

[36]  J. Allen,et al.  Neutralization of dengue virus in the presence of Fc receptor-mediated phagocytosis distinguishes serotype-specific from cross-neutralizing antibodies. , 2012, Antiviral research.

[37]  I. Wilson,et al.  Networks link antigenic and receptor-binding sites of influenza hemagglutinin: Mechanistic insight into fitter strain propagation , 2011, Scientific reports.

[38]  Hugues Bedouelle,et al.  Mechanism of dengue virus broad cross-neutralization by a monoclonal antibody. , 2012, Structure.

[39]  J. Connolly,et al.  Leukocyte immunoglobulin-like receptor B1 is critical for antibody-dependent dengue , 2014, Proceedings of the National Academy of Sciences.

[40]  E. Harris,et al.  A potent anti-dengue human antibody preferentially recognizes the conformation of E protein monomers assembled on the virus surface , 2014, EMBO molecular medicine.

[41]  J. Whittle,et al.  Structural and genetic basis for development of broadly neutralizing influenza antibodies , 2012, Nature.

[42]  M. Beltramello,et al.  In-Depth Analysis of the Antibody Response of Individuals Exposed to Primary Dengue Virus Infection , 2011, PLoS neglected tropical diseases.

[43]  Rana F. Hamdy,et al.  Efficacy of a Tetravalent Dengue Vaccine in Children in Latin America. , 2015, Journal of the Pediatric Infectious Diseases Society.

[44]  John S. Brownstein,et al.  The global distribution and burden of dengue , 2013, Nature.

[45]  P. Lambert,et al.  Determinants of infant responses to vaccines in presence of maternal antibodies. , 1998, Vaccine.

[46]  K. Swiderek,et al.  Efficacy and safety of treatment with an anti-m2e monoclonal antibody in experimental human influenza. , 2015, The Journal of infectious diseases.